Novel Sepsis Sub-phenotypes Based on Trajectories of Vital Signs
Implementation and Prospective Validation of a Sepsis Sub-phenotyping Algorithm Based on Vital Sign Trajectories
3 other identifiers
observational
1,916
1 country
4
Brief Summary
Sepsis is a dysregulated host response to infection resulting in organ dysfunction. Over the past three decades, more than 30 pharmacological therapies have been tested in \>100 clinical trials and have failed to show consistent benefit in the overall population of patients with sepsis. The one-size-fits-all approach has not worked. This has resulted in a shift in research towards identifying sepsis subphenotypes through unsupervised learning. The ultimate objective is to identify sepsis subphenotypes with different responses to therapies, which could provide a path towards the precision medicine approach to sepsis. The investigators have previously discovered sepsis subphenotypes in retrospective data using trajectories of vital signs in the first 8 hours of hospitalization. The team aims to prospectively classify adult hospitalized patients into these subphenotypes in a prospective, observational study. This will be done through the implementation of an electronic health record integrated application that will use vital signs from hospitalized patients to classify the patients into one of four subphenotypes. This study will continue until 1,200 patients with infection are classified into the sepsis subphenotypes. The classification of the patients is only performed to validate the association of the subphenotypes with clinical outcomes as was shown in retrospective studies. Physicians and providers treating the patients will not see the classification, and the algorithm classifying the patients will in no way affect the care of the patients. Further, all the data needed for the algorithm (vital signs from the first 8 hours) are standard of care, and enrollment in the prospective study does not require any additional data.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Sep 2025
Shorter than P25 for all trials
4 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 12, 2023
CompletedFirst Posted
Study publicly available on registry
April 24, 2023
CompletedStudy Start
First participant enrolled
September 18, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 14, 2026
CompletedStudy Completion
Last participant's last visit for all outcomes
January 14, 2026
CompletedFebruary 23, 2026
February 1, 2026
4 months
April 12, 2023
February 20, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
In-hospital mortality
Comparison of 30 day in-hospital mortality rate between the 4 subphenotypes.
Up to 30 days
Secondary Outcomes (7)
Renal replacement therapy (RRT)
Through study completion, on average 30 days
Mechanical ventilation
Through study completion, on average 30 days
Vasopressor use
Through study completion, on average 30 days
Inotrope use
Through study completion, on average 30 days
Admission to the intensive care unit (ICU)
Through study completion, on average 30 days
- +2 more secondary outcomes
Interventions
The algorithm will run silently in the background and continuously compute the subphenotypes of patients who are presenting to the emergency department (ED) with suspected infection.
Eligibility Criteria
All adult patients who present to the emergency department at the participating facilities will automatically be enrolled in the study until the enrollment target for the study is met. All patients will be classified into subphenotypes using the algorithm, but the subgroup that will be analyzed will be patients with suspected infection.
You may qualify if:
- All adults who present to the emergency department
You may not qualify if:
- None
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (4)
Emory Hospital Midtown
Atlanta, Georgia, 30308, United States
Emory Saint Joseph's Hospital
Atlanta, Georgia, 30308, United States
Emory University Hospital
Atlanta, Georgia, 30322, United States
Emory Johns Creek Hospital
Johns Creek, Georgia, 30097, United States
Related Publications (1)
Bhavani SV, Semler M, Qian ET, Verhoef PA, Robichaux C, Churpek MM, Coopersmith CM. Development and validation of novel sepsis subphenotypes using trajectories of vital signs. Intensive Care Med. 2022 Nov;48(11):1582-1592. doi: 10.1007/s00134-022-06890-z. Epub 2022 Sep 24.
PMID: 36152041RESULT
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Sivasubramanium Bhavani, MD
Emory University
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Assistant Professor
Study Record Dates
First Submitted
April 12, 2023
First Posted
April 24, 2023
Study Start
September 18, 2025
Primary Completion
January 14, 2026
Study Completion
January 14, 2026
Last Updated
February 23, 2026
Record last verified: 2026-02
Data Sharing
- IPD Sharing
- Will not share